Xencor Q4 revenue misses expectations, net loss narrows

Xencor

25/02/2026 21:18

Overview

Biopharmaceutical firm's Q4 revenue missed analyst expectations

Net loss for Q4 narrowed to $6.7 mln from $45.6 mln last year

Company plans to present clinical data for XmAb819 in 2H26

Outlook

Xencor expects to end 2026 with $400 mln to $430 mln in cash

Company plans to initiate pivotal study of XmAb819 in 2027

Xencor anticipates royalty revenue from Xtend patent extension through 2028

Result Drivers

REVENUE DECLINE - Q4 revenue fell due to lower collaboration and royalty income

HIGHER R&D COSTS - Increased R&D expenses driven by higher costs for pipeline programs

Company press release: ID:nBw6qrBM8a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$28.20 mln
$31.69 mln (11 Analysts)
Q4 EPS
-$0.09
Q4 Net Income
-$6.65 mln
Q4 Operating Expenses
$81.87 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Xencor Inc is $27.00, about 128.6% above its February 24 closing price of $11.81

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)